Your search relates to more than one category
The Puget Sound Business Journal (Free subscription) | 11/20/2009
Dendreon Corp. said the U.S. Food and Drug Administration said it will make a regulatory decision on the biotech’s Provenge prostate cancer drug by May 1, 2010. (DNDN)
Seattle Times (Free subscription) | 11/20/2009
Biotechnology company Dendreon Corp. said Friday the Food and Drug Administration will make a regulatory decision on the potential prostate cancer vaccine Provenge by May 1.
Seattle Post-Intelligencer (Free subscription) | 11/20/2009
SEATTLE -- Biotechnology company Dendreon Corp. said Friday the Food and Drug Administration will make a regulatory decision on the potential prostate cancer vaccine Provenge by May 1.
The Puget Sound Business Journal (Free subscription) | 11/11/2009
Dendreon Corp. reported a third-quarter loss of $45.6 million, or a loss of 40 cents per share, which compares with a loss of $26.8 million, or a loss of 29 cents a share a year earlier. (DNDN)
GuruFocus Updates (Free subscription) | 11/09/2009
By 10qk. Dendreon Corp. ( DNDN ) filed Quarterly Report for the period ended 2009-09-30. Read more » »
Investment U (Free subscription) | 11/06/2009
Dendreon Corp. (Nasdaq: DNDN): Put Two Promising Biotech Stocks on Your Watch List by Louis Basenese, Small Cap and Special Situations Expert Friday, November 6, 2009: Issue #1132 All the hoopla surrounding the biotech stock, Dendreon Corp. (Nasdaq: DNDN), this year is well deserved. After all, the market potential for its prostate cancer treatment, Provenge, is significant....
Investment U (Free subscription) | 11/06/2009
Dendreon’s Reached Orbit… Now Who’s Next? by Robert Williams, Publisher When the opening bell rang on Tuesday morning, as the broader market sagged, shares of Dendreon Corp. (Nasdaq: DNDN) sprinted out of the gates, rising by 5.7%. Unless you live in a cave, you should know about this biotech stock. Back in April, shares went [...]
Volume Spike Investor (Free subscription) | 11/02/2009
Dendreon Corp. (NASDAQ: DNDN) is trading higher on word from the company that it has filed its new drug application with the FDA for PROVENGE to treat prostate cancer. The notion of the filing is not new, although many were not expecting this filing to be submitted until later in November or in December. At [...]
The Puget Sound Business Journal (Free subscription) | 11/02/2009
Seattle biotechnology company Dendreon Corp. said Monday it had filed an application for its lead drug candidate, Provenge, to the U.S. Food and Drug Administration. (DNDN)
Market Wire (Free subscription) | 11/12/2009
... (NASDAQ: ADSK), Huntington Bancshares Inc. (NASDAQ: HBAN), Finish Line Inc. (NASDAQ: FINL) and Dendreon Corp. (NASDAQ: DNDN).
Market Wire (Free subscription) | 11/03/2009
... Inc. (NASDAQ: EWBC), Fifth Third Bancorp (NASDAQ: FITB), Bare Escentuals Inc. (NASDAQ: BARE) and Dendreon Corp. (NASDAQ: DNDN).
Stock Market Analysis (Free subscription) | 11/02/2009
... IRB Approval Terra Industries Inc. (TRA) - CF Industries boosts cash portion of Terra offer Kopin Corp. (KOPN) - Reports record revenues Vertex Pharmaceuticals Incorporated (VRTX) - Vertex hep C drug works well in twice daily dosing Progressive Corp. (PGR) - Bullish comments from Barron's Labopharm Inc. (DDSS) - Labopharm to host conference call Friday, November 6, 2009 at 10:00 a.m....
24/7 Wall St. (Free subscription) | 11/02/2009
This is a strange morning for day trader alerts. There are not dozens and dozens of stocks in the big news, but those that are moving are moving big. We have links through on each stock over at VSInvestor.com for more data and analysis on price and volume: CIT Group Inc. (NYSE: CIT) is actually very thin volume as no NYSE trades are seen, but it is down by almost half on its bankruptcy filing. Dendreon...
